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The Dual Amylin- and Calcitonin-Receptor Agonist KBP-042
Increases Insulin Sensitivity and Induces Weight Loss
in Rats with Obesity
Sara Toftegaard Hjuler1, Sofie Gydesen1, Kim Vietz Andreassen1, Steffen Lund Kjær Pedersen1, Lars I. Hellgren2,
Morten Asser Karsdal1, and Kim Henriksen1
Objective: In this study, KBP-042, a dual amylin- and calcitonin-receptor agonist, was investigated as a
treatment of obesity and insulin resistance in five different doses (0.625 mg/kg–10 mg/kg) compared with
saline-treated and pair-fed controls.
Methods: Rats with obesity received daily s.c. administrations for 56 days, and glucose tolerance was
assessed after one acute injection, 3 weeks of treatment, and again after 7 weeks of treatment. To
assess the effect on insulin sensitivity, rats received 5 mg/kg KBP-042 for 21 days before hyperinsuline-
mic–euglycemic clamp.
Results: KBP-042 induced a sustained weight loss of up to 20% without any significant weight reduction
in the pair-fed groups. Decreases in adipose tissues and lipid deposition in the liver were observed, while
plasma adiponectin was increased and plasma leptin levels were decreased. Acute administration of
KBP-042 led to impaired glucose tolerance and increased plasma lactate, while this diabetogenic effect
was reversed by chronic treatment. Finally, assessment of insulin sensitivity using the hyperinsulinemic–
euglycemic clamp showed that KBP-042 increased the glucose infusion rate.
Conclusions: The study indicates that KBP-042 combines two highly relevant features, namely weight
loss and insulin sensitivity, and is thus an excellent candidate for chronic treatment of obesity and insulin
resistance.
Obesity (2016) 24, 1712–1722. doi:10.1002/oby.21563
Introduction
Obesity is one of the greatest public health challenges of the 21st
century (1). Obesity can lead to insulin resistance and type 2 diabe-
tes (2), which are associated with a range of metabolic dysfunctions
(3,4). Weight loss, improved glycemic control, and increased insulin
action to reduce strain on the b cells are key points for improving
disease status. This can be achieved by different interventions (exer-
cise, diet, medication, surgery) which all cause improvements in
metabolic profiles and increase of insulin sensitivity and b-cell func-
tion (5,6). However, as lifestyle changes often result in only minor
weight reductions followed by a rapid regain of weight (7), there is
a need for treatments targeting multiple factors of the obesity-related
diseases. These include insulin resistance and b-cell failure to avoid
development of type 2 diabetes, as well as diabetic complications.
Activation of amylin receptors has already been linked with reduc-
tion of food intake (8), increased responsiveness to leptin (9-11),
weight loss (12,13), and indications of increased energy expenditure
(11,13-16). However, amylin is a short-lasting agonist in vivo, and
there is a need for improved ligands. KBP-042 is a dual amylin- and
calcitonin-receptor agonist with highly potent antiobesity and anti-
diabetic effects (17), although a long-term chronic treatment has not
yet been tested.
In this study, KBP-042 was tested in a long-term treatment of predia-
betic rats with obesity, in order to evaluate KBP-042’s potential as a
chronic treatment of obesity. We further examined whether the bene-
ficial effects on glucose homeostasis were maintained throughout the
study, and finally we investigated whether treatment with KBP-042
could increase insulin sensitivity and reduce hepatic steatosis.
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Recombinant KBP-042 peptide (Unigene Laboratories, Boonton, NJ)
was dissolved in saline for subcutaneous (s.c.) delivery. The doses
for KBP-042 administration in the studies were based on previous
studies in animal models of obesity and type 2 diabetes and ranged
from 10 mg/kg to 0.625 mg/kg (2.87–0.18 nmol/kg/day) (17,18).
Animal experiments
All animal procedures were performed in accordance with guidelines
from the Animal Welfare Division of the Danish Ministry of Justice
under the institutional license issued to Nordic Bioscience (2012-15-
2934-00094). All male Sprague Dawley rats were obtained at 6
weeks of age and housed under controlled temperature (208C6 2)
on a normal 12-h light–dark cycle with ad libitum access to water
and food. Normal diet control rats (ND) were fed rodent chow
(5002, LabDiet, St. Louis, MO) and high-fat diet (HFD) rats a 60%
fat kcal diet (#D12495, Research Diets Inc., NJ). After 10 weeks of
high-fat feeding rats were assigned into groups (n5 10) and con-
trolled for equal mean body weight.
Acute study. Food was removed in the afternoon (4 p.m.). After
16 to 18 h of fasting an oral glucose tolerance test (OGTT) was per-
formed. Rats received a single dose of saline (vehicle) or peptide
(10 mg/kg, 5 mg/kg, 2.5 mg/kg, 1.25 mg/kg, 0.625 mg/kg). After 30
min, a glucose bolus (2 g/kg, Sigma-Aldrich, Copenhagen, Den-
mark) was administered by oral gavage. Blood glucose was moni-
tored by Accu-CheckVR Avia monitoring system (Roche Diagnostics,
Rotkreuz, Switzerland) and EDTA-plasma was obtained from the
lateral tail vein at t5 0, 15, 30, 60, and 120 min.
Pica test. Fasted animals were administered s.c. with 5, 10, or 50
mg/kg KBP-042 or vehicle (saline). After dosing, animals had free
access to normal chow or kaolin pellets (5TBP, Test diet, MO) and
food and kaolin intake was monitored after 4 and 24 h.
Chronic study. Each rat was dosed once daily with either saline
(vehicle, pair-fed 5 mg/kg, pair-fed 10 mg/kg) or KBP-042 (10 mg/kg,
5 mg/kg, 2.5 mg/kg, 1.25 mg/kg, 0.625 mg/kg) in the afternoon for 8
weeks. The two pair-fed groups were food restricted to match the daily
food intake of their corresponding treatment groups (5 mg/kg or 10 mg/
kg). Pair-fed animals received an average of the daily intake of their
treated paired group every day in the afternoon. Food intake and body
weight were monitored daily for the first 6 days, then weekly. OGTT,
performed as in the acute study and intravenous glucose tolerance tests
(IVGTT) were performed after 3 and 7 weeks of treatment. IVGTT
was performed in the morning after 18 h of fasting. Each rat received
a single dose of either saline (vehicle, pair-fed 5 mg/kg, pair-fed 10
mg/kg) or peptide (10 mg/kg, 5 mg/kg, 2.5 mg/kg, 1.25 mg/kg, 0.625 mg/
kg), after 30 min glucose (0.5 g/kg, Sigma-Aldrich, Copenhagen, Den-
mark) was administered in the lateral tail vein and blood glucose was
monitored and EDTA-plasma was obtained at t5 0, 5, 15, 30, 60, and
120 min, as described above. To assess effect on gastric emptying,
overnight-fasted rats received s.c. KBP-042 injection, were adminis-
tered 40 mg/kg acetaminophen by oral gavage (4 mL/kg) after 30 min
and the appearance of acetaminophen in plasma was monitored (19).
Blood was collected 30 min after administration from the tail vein and
acetaminophen levels were measured in EDTA-plasma (Acetamino-
phen Direct ELISA Kit, Immuneanalysis, Pomona, CA). Gastric emp-
tying was calculated as % change relative to ND rats.
After 8 weeks, EDTA-Aprotinin plasma samples were collected for
hormonal analyses after 3 h fasting. Animals were euthanized under
isoflurane inhalation followed by exsanguination. Excised tissue was
snap-frozen in liquid nitrogen and stored at 2808C, and plasma was
stored at 2208C samples until further analysis.
Hyperinsulinemic–euglycemic clamp
Insulin-mediated whole body glucose uptake was estimated in rats fed
either HFD or ND (as described above). The HFD rats were stratified
into HFD vehicle or HFD-KBP-042 groups (n5 5–7). ND vehicle
and HFD vehicle rats received saline injections while HFD-KBP-042
received 5 mg/kg of KBP-042 s.c. for 21 days. After the treatment
period, animals were subjected to a hyperinsulinemic–euglycemic
clamp experiment explained in details in the Supporting Information.
Plasma analysis
Plasma levels of lactate (L-lactate colorimetric assay, Abcam, Cam-
bridge, UK), insulin (Mercodia Rat Insulin ELISA, Mercodia AB,
Uppsala, Sweden), leptin (Rat Leptin ELISA, Millipore Corporation,
Billerica, MA), glucose-dependent insulinotropic peptide (GIP) (Rat/
Mouse GIP (Total) ELISA, Merck Millipore, Billerica, MA), and
adiponectin (Rat Adiponectin ELISA, Millipore Corporation, Biller-
ica, MA) were analyzed according to manufacturers instruction.
Tissue analysis
Lipids were extracted from liver samples with addition of internal
standards and triacylglycerol (TAG) was isolated from the total lipid
extract using aminopropyl solid-phase extraction cartridges, trans-
methylated, and quantified using Gas Chromatography–Flame Ioni-
zation Detector as previously described (20).
Statistical analysis
Data were statistically analyzed by one-way ANOVA multiple com-
parison followed by Tukey’s test. In Supporting Information Table
S1, ND controls were compared with HFD vehicle using Student’s
t-test. Values of P < 0.05 were considered to be significant.
Results
KBP-042 mediated substantial and sustained
reductions in body weight
The baseline characteristics of HFD rats and lean controls confirmed
the obese and prediabetic status of the HFD rats (Supporting Infor-
mation Table S1).
After treatment with KBP-042 for 8 weeks, a dose-dependent and sus-
tained reduction of body weight was observed. A large weight loss
was observed in the initial phase of the study (Figure 1A, B) in the
three highest treatment groups (2.5 mg/kg, 5 mg/kg, and 10 mg/kg), as
well as the two corresponding pair-fed groups (pair-fed 5 mg/kg and
pair-fed 10 mg/kg). This corresponds well with the large reduction in
food intake in the first 6 days of treatment (Figure 1D). Due to the
drastic reduction in food intake, pica behavior was tested as a surro-
gate for nausea in rats. The two highest doses, 5 and 10 mg/kg KBP-
042 did not give rise to kaolin intake whereas a high dose of KBP-
042 not used in this study (50 mg/kg) provoked pica behavior
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Figure 1 (A) Body weight progression in % of initial body weight during the study from randomization at day 0 to last day of treatment, day 56. (B) Vehicle-
corrected body weights. (C) End point body weights. (D) Food intake of all treatment groups during the entire study. Food intake was monitored every day for
the first 6 days followed by weekly monitoring. Pair-fed groups were fed the same as the average for their corresponding treatment group (5 mg/kg or 10 mg/kg).
(E) Accumulated food intake for the entire duration of the study expressed in kcal/2 animals. (F) Calculated food efficiency. n5 10 for all groups except vehicle
(n5 12). Statistical analysis between groups for panels C, E, and F performed as a one-way ANOVA followed by Tukey’s post hoc test with the following annota-
tions: ###P< 0.001 vs. normal diet control (ND). *P< 0.05, ***P< 0.001 vs. high-fat diet (HFD) vehicle. ††P< 0.01, †††P< 0.001 vs. pair-fed 5 mg/kg.
‡‡P< 0.01, ‡‡‡P< 0.001 vs. pair-fed 10 mg/kg. Data are expressed as mean6SEM. [Color figure can be viewed in the online issue, which is available at
wileyonlinelibrary.com.]
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(Supporting Information Figure S1). After the transient reduction in
feeding, food intake increased during the study. The pair-fed groups
gained weight again after feeding increased; inversely, treatment with
KBP-042 sustained the initial weight reduction throughout the 56 days,
with significant reductions in the 2.5 mg/kg, 5 mg/kg, and 10 mg/kg
groups compared with the HFD vehicle (Figure 1C). The accumulated
food intake corresponds well with the weight change for the three high-
est treatment groups (2.5 mg/kg, 5 mg/kg, and 10 mg/kg) (Figure 1E),
although the pair-fed groups which received the same amount of food as
their corresponding treatment group did not lose significant weight.
Accordingly, treatment with 2.5, 5, and 10 mg/kg KBP-042 resulted in
drastic and significant reduction in food efficiency compared with pair-
fed (Figure 1F), suggesting increased energy expenditure.
KBP-042 reduced adipose tissue and ectopic
lipid accumulation
After treatment three different adipose tissues were isolated and as
seen in Figure 2A–C, the weights of isolated epididymal and perire-
nal adipose tissues were significantly reduced after treatment with
10 mg/kg of KBP-042. The perirenal adipose tissue in the 2.5, 5, and
10 mg/kg groups was reduced significantly while inguinal fat was
not. The same reduction was not seen in the pair-fed controls.
Lipid accumulation in liver was assessed as hepatic TAG concentra-
tion (Figure 2D). As expected the HFD vehicle group had dramati-
cally higher TAG levels compared with ND group. This accumula-
tion was significantly reduced after treatment with KBP-042 (10 mg/
kg), while the corresponding pair-fed control group did not show a
significant reduction in liver TAG. In order to assess the treatment
effect on fatty acid metabolism in selective ways (e.g. metabolism
of saturated vs. monounsaturated vs. polyunsaturated), the fatty acid
composition of hepatic TAG was analyzed. The results showed that
there was no difference in the relative distribution, i.e., the treatment
caused a general reduction in TAG without effecting the metabolism
of specific fatty acid types (Supporting Information Table S2).
Finally, adiponectin and leptin levels were measured after 56 days of
treatment (Figure 2E, F). Adiponectin was significantly increased in
response to treatment with all doses of KBP-042 except 0.625 mg/kg.
For plasma leptin a statistically significant reduction was seen when
comparing 10 mg/kg KBP-042 with the corresponding pair-fed control.
In summary, fat depots, lipid, and adipokine data support a strongly
improved metabolic status as a function of treatment with KBP-042.
Chronic treatment with KBP-042 improved
glucose tolerance with reduced insulin levels
OGTT was performed after the first injection, as well as after 3 and
7 weeks of treatment.
The acute OGTT showed a slightly impaired glucose tolerance for
the 10 mg/kg group compared with HFD vehicle (Figure 3A, D). A
hyperglycemic effect was observed 30 min after s.c. administration
of KBP-042 at t5 0 compared with vehicle (5.9 mM) for 5 mg/kg
(6.8 mM, P 5 0.033) and for 10 mg/kg (7.4 mM, P < 0.001)
groups. The total area under the curve (tAUC) was significantly
increased after injection of 10 mg/kg KBP-042 (Figure 3D). How-
ever, the insulin levels during the first 60 min after glucose adminis-
tration were reduced in animals dosed with KBP-042 (Figure 3G, J).
After 3 weeks of treatment with KBP-042 or saline, the three high-
est doses of KBP-042 resulted in a significantly lowered tAUC (Fig-
ure 3B, E). Insulin levels were lowered by KBP-042 except in the
0.625 mg/kg group (Figure 3H, K). Pair-fed 10 mg/kg group also had
a reduced insulin response (Figure 3K).
During OGTT after week 7 (Figure 3C) the two highest dose groups
had improved glucose tolerance when tAUC was considered (Figure
3F). The two highest dose groups showed increased glucose tolerance,
while drastically reduced insulin levels were observed within the first
60 min after glucose administration (Figure 3I, L). Pair-feeding did
not change glucose handling compared with HFD vehicle.
After administration of KBP-042, plasma lactate was dose-
dependently increased in treatment of naive animals (Supporting
Information Figure S2A) and resulted in a 1.5 mM increase in plasma
lactate 30 min after s.c. administration of 10 mg/kg KBP-042. Interest-
ingly, the KBP-042-provoked lactate response was completely blunted
by chronic treatment (Supporting Information Figure S2B, C).
KBP-042 reduced gastrointestinal mobility and
plasma levels of the gut hormone GIP
The rate of gastric emptying during OGTT was assessed in response
to acute dosing with KBP-042, after treatment for 3 weeks, or after
7 weeks (Figure 4A, C, E, respectively). Acute s.c. administration of
KBP-042 resulted in a significant reduction of gastric emptying 30
min after acetaminophen administration for the three highest treat-
ment groups (2.5 mg/kg, 5 mg/kg, and 10 mg/kg) (Figure 4A). In ani-
mals treated for 3 weeks with KBP-042, gastric emptying was
reduced for all treatment groups. The two pair-fed groups displayed
a slower rate of gastric emptying due to food restriction; however,
they still have significantly higher rates of gastric emptying com-
pared with 5 mg/kg and 10 mg/kg groups of KBP-042 (Figure 4C).
After 7 weeks of treatment the reduced gastric emptying was still
significant at most doses compared with HFD vehicle. The pair-fed
groups were no longer different from the HFD controls (Figure 4E).
GIP levels in plasma were quantified 0 to 30 min after acute glucose
administration, and after 3 and 7 weeks of treatment (Figure 4B, D,
F). After acute administration of KBP-042, GIP levels were signifi-
cantly lower in the groups treated with 2.5 to 10 mg/kg KBP-042
(Figure 4B). After treatment for 3 weeks, all groups displayed a
drastic reduction in plasma GIP. The two pair-fed groups demon-
strated significantly lowered GIP levels compared with HFD vehicle
probably due to food restriction. They were still significantly higher
than their corresponding treatment controls (5 mg/kg and 10 mg/kg)
(Figure 4D). After 7 weeks of treatment, plasma GIP levels were
reduced; however, the changes were only significant in the three
highest treatment groups. The reductions in pair-fed groups were no
longer present after 7 weeks of treatment (Figure 4F).
KBP-042 maintained peripheral glucose tolerance
with lower insulin levels irrespective of altered
gastric emptying
To circumvent the gastrointestinal tract and assess peripheral glu-
cose tolerance, IVGTTs were performed after 3 and 7 weeks of
treatment (Figure 5). In both tests, all KBP-042 groups showed a
trend towards lower blood glucose compared with vehicle and pair-
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Figure 2 (A–C) Weight of isolated epididymal, inguinal, and perirenal white adipose tissue (WAT), respectively, after 56 days of treatment. (D) Total tri-
acylglyceride content extracted from liver tissue after treatment with KBP-042 or saline for 56 days. (E,F) Plasma adiponectin and leptin levels,
respectively, after 56 days of treatment. n5 10 for all groups except vehicle (n5 12). Statistical analysis between groups performed as a one-way
ANOVA followed by Tukey’s post hoc test with the following annotations: ##P< 0.01, ###P< 0.001 vs. normal diet control (ND). *P< 0.05,
**P< 0.01, ***P< 0.001 vs. high-fat diet (HFD) vehicle. †P< 0.05, ††P< 0.01 vs. pair-fed 5 mg/kg. ‡P< 0.05 vs. pair-fed 10 mg/kg. Data are
expressed as mean6SEM.
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fed controls 5 and 10 min after glucose administration (Figure 5A,
B). This manifested in a lowered tAUC0–120 min for the 2.5 mg/kg
KBP-042 group only in the first test after 3 weeks and not after 7
weeks of treatment. No effect was observed for pair-fed groups.
Interestingly, when insulin levels were quantified, the tAUC for
insulin was significantly reduced in KBP-042 1.25-10 mg/kg groups
after 3 weeks of treatment (Figure 5G). After 7 weeks of treatment,
groups treated with 2.5 mg/kg and 5 mg/kg KBP-042 had
Figure 3 Blood glucose and insulin levels during oral glucose tolerance test (OGTT) performed in animals treated with KBP-042 or vehicle once (left), for 3
weeks (middle), or 7 weeks (right). Animals were challenged with an oral glucose bolus (2 g/kg) at time5 0 and dosed with either KBP-042 or saline at
t5230. (A–C) Blood glucose levels during acute OGTT, OGTT after 3 weeks, and OGTT after 7 weeks, respectively. (D–F) Area under the curve (AUC) for
acute OGTT, OGTT after 3 weeks, and OGTT after 7 weeks, respectively. (G–I) Insulin levels during acute OGTT, OGTT after 3 weeks, and OGTT after 7
weeks, respectively. (J-L) Insulin levels during acute OGTT, OGTT after 3 weeks, and OGTT after 7 weeks, respectively, expressed as AUC. n5 10 for all
groups except vehicle (n5 12). Statistical analysis between groups performed as a one-way ANOVA followed by Tukey’s post hoc test with the following
annotations: *P< 0.05, **P< 0.01, ***P< 0.001 vs. high-fat diet (HFD) vehicle. ††P< 0.01, †††P<0.001 vs. pair-fed 5 mg/kg. ‡‡P< 0.01, ‡‡‡P< 0.001 vs.
pair-fed 10 mg/kg. Data are expressed as mean6SEM. [Color figure can be viewed in the online issue, which is available at wileyonlinelibrary.com.]
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Figure 4 (A) Relative rates of gastric emptying measured 30 min after glucose challenge in the oral glucose tolerance test (OGTT) performed in treat-
ment naive animals. (B) Area under the curve (AUC) of plasma levels of glucose-dependent insulinotropic peptide (GIP) during OGTT in treatment naive
animals up to 30 min after glucose challenge. (C) Relative rates of gastric emptying measured 30 min after glucose challenge in the OGTT performed
animals treated with KBP-042 for 3 weeks. (D) AUC of plasma levels of GIP during OGTT in animals treated for 3 weeks, up to 30 min after glucose
challenge. (E) Relative rates of gastric emptying measured 30 min after glucose challenge in the OGTT performed animals treated with KBP-042 for 7
weeks. (F) AUC of plasma levels of GIP during OGTT in animals treated for 7 weeks, up to 30 min after glucose challenge. n5 10 for all groups
except high-fat diet (HFD) vehicle (n512). Statistical analysis between groups performed as a one-way ANOVA followed by Tukey’s post hoc test
with the following annotations: *P< 0.05, **P< 0.01, ***P< 0.001 vs. HFD vehicle. ††P< 0.01, †††P< 0.001 vs. pair-fed 5 mg/kg. ‡‡P< 0.01,
‡‡‡P< 0.001 vs. pair-fed 10 mg/kg. Data are expressed as mean6SEM.
Obesity KBP-042, a Weight Loss Drug and Insulin Sensitizer Hjuler et al.
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Figure 5.
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significantly reduced insulin levels while maintaining glucose toler-
ance (Figure 5H).
KBP-042 improved whole body insulin sensitivity
in the hyperinsulinemic–euglycemic clamp
A hyperinsulinemic–euglycemic clamp study was performed to
address the effect of KBP-042 on insulin sensitivity. For this study,
ND rats were compared with insulin-resistant HFD rats and 5 mg/kg
KBP-042 treated HFD rats. Figure 6A shows GIR reduced by 30%
(P 5 0.057) in the HFD group compared with ND. The treatment
with KBP-042 led to a significant increase in GIR (82%, P <
0.001) compared with HFD vehicle. When KBP-042 treatment is
compared with ND, GIR is increased with 27% (P < 0.05). As
expected, body weight was increased after HFD for 10 weeks as
compared with ND (Figure 6B), but treatment with KBP-042 for 21
days reduced weight with 18%, and the body weight was not sig-
nificantly different from the ND rats at the end of the study.
Discussion
In this study, KBP-042 induced a significant weight loss over a
period of 8 weeks, albeit with dramatic reductions in food intake
initially. Kaolin consumption was, however, only stimulated in a
higher dose than used in this study, thus indicating the reduction in
food intake was not due to illness. However, minor nausea in the
rats cannot be excluded. The highest KBP-042 groups sustain the
weight loss (up to 20% compared with HFD vehicle) throughout the
study, a phenomenon not seen in the pair-fed groups. The decreased
food efficiency of the KBP-042-treated rats (2.5 mg/kg–10 mg/kg)
and the large weight difference between treated and pair-fed rats,
indicate increased energy expenditure. In general, amylin agonism
blunts the reduction of energy expenditure that is normally caused
by food restriction and weight loss, as well as changing RER
(11,21), an indicator of fat utilization. Interestingly, amylin only
increases energy expenditure when given as chronic infusion s.c. or
i.c.v. (15,16,22), a finding likely related to short-lived activity of
amylin (23). KBP-042 has a longer and more potent activation pro-
file (17), despite a fast disappearance from plasma (<120 min) (18).
However, energy expenditure, as well as potential fecal energy
losses have to be formally assessed in future studies.
KBP-042 was able to significantly reduce TAG accumulation in the
liver at both 2.5 mg/kg and 10 mg/kg. The reduction did not reach a
significant level at 1.25 mg/kg and 5.0 mg/kg due to the relatively
large individual variations in the hepatic TAG levels, but there is a
tendency towards reduced hepatic TAG in these groups. Since
ectopic deposition of lipids in the liver is related to increased insulin
resistance, reducing the hepatic lipid-load could improve hepatic
insulin sensitivity, hereby reducing gluconeogenesis in the fatty liver
and increasing glucose tolerance (24). As of today, weight loss is
the only remedy for ectopic lipid deposition, and KBP-042 serves as
an excellent drug candidate to mediate this in an efficient manner.
However, the extent to which a similar effect could be obtained by
matching the weight loss remains to be explored. Importantly, the
Figure 5 (A,B) Intravenous glucose tolerance test (IVGTT) performed in animals treated for 3 weeks and 7 weeks, respectively, with either KBP-042 or
saline. Animals were dosed s.c. at t5230 and received i.v. glucose challenge at t50. (C) Area under the curve (AUC) 0 to 120 min for the IVGTT in
panel A performed after treatment with KBP-042 for 3 weeks. (D) AUC 0 to 120 min for the IVGTT in panel B performed after treatment with KBP-042 for
7 weeks. (E) Plasma insulin levels during the IVGTT performed after 3 weeks of treatment. (F) Plasma insulin levels during the IVGTT performed after 7
weeks of treatment (legends as for panel A). (G) AUC for plasma insulin levels 0 to 30 min after glucose challenge in the IVGTT in panel A performed after
treatment with KBP-042 for 3 weeks (legends as for panel B). (H) AUC for plasma insulin levels 0 to 30 min after glucose challenge in the IVGTT in panel
B performed after treatment with KBP-042 for 7 weeks. n510 for all groups except high-fat diet (HFD) vehicle (n5 12). Statistical analysis between
groups performed as a one-way ANOVA followed by Tukey’s post hoc test with the following annotations: *P< 0.05, ***P< 0.001 vs. HFD vehicle.
†P< 0.05, †††P< 0.001 vs. pair-fed 5 mg/kg. ‡P< 0.05, ‡‡P< 0.01 vs. pair-fed 10 mg/kg. Data are expressed as mean6SEM. [Color figure can be
viewed in the online issue, which is available at wileyonlinelibrary.com.]
Figure 6 (A) Glucose infusion rate (GIR) at steady state during hyperinsulinemic–euglycemic clamp when blood glucose was clamped
at basal levels after 21 days of treatment. (B) Body weight at hyperinsulinemic–euglycemic clamp experiment day after 21 days of
treatment. Statistical analysis between groups performed as a one-way ANOVA followed by Tukey’s post hoc test with the following
annotations: *P< 0.05, **P< 0.01, ***P< 0.001. Data are expressed as mean6SEM.
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analysis of the fatty acid composition of TAG further suggests that
the fatty acid metabolism in the liver is unaltered, and the changes
are an overall TAG reduction.
During acute OGTT, increases in plasma lactate and blood glucose
were seen 30 min after administration of KBP-042, corresponding to
previous studies showing acute hyperglycemia following acute admin-
istration of salmon calcitonin or rat amylin (25). This is likely
explained by inhibition of insulin secretion, but also increased plasma
lactate as seen in this study. This manifested as a tendency towards
impaired glucose tolerance. Interestingly, the increase in plasma lac-
tate was not present in animals treated chronically. In fact, chronic
treatment led to improved oral glucose tolerance compared with both
vehicle and pair-fed groups. Importantly, the improved glucose clear-
ance was achieved with significantly lower plasma insulin levels, indi-
cating improved insulin action. The improved glucose tolerance
together with reduced liver TAG supports a general improved metabo-
lism and insulin sensitivity. This is further supported by the reduction
in adiposity, as plasma adiponectin is reduced in subjects who have
obesity and related to for example, inflammation, insulin resistance,
and energy metabolism (26,27), as well as type of phenotype in differ-
ent fat depots (28). The observed increase in adiponectin is in align-
ment with the improvement in both glucose tolerance and insulin
action as well as fatty acid removal from liver that KBP-042 induces
(26,29-31). The reduced adiposity also manifested in lowering of
plasma leptin, which corresponds well with previous demonstrations
that KBP-042 increases the sensitivity towards leptin (18), a finding
also seen with amylin (14,32).
IVGTT was performed to assess peripheral glucose homeostasis
while circumventing the gastrointestinal system, which is obviously
very affected by amylin agonism such as KBP-042 (33,34). Rats
treated with KBP-042 maintained glucose tolerance with reduced
insulin levels hence implying improved insulin sensitivity, albeit
with an effect markedly lower than in the OGTT. This corroborates
that KBP-042 has gastric emptying-independent effects on glucose
tolerance. The reduced insulin levels both during IVGTT and OGTT
could be explained by a direct KBP-042-mediated inhibition of both
insulin and glucagon secretion directly in the islets of Langerhans
(17), but maintaining or improving glycemia, glucose disposal rate,
and insulin action after a significant weight loss is also well
described in humans (5).
Plasma GIP levels and gastric emptying was assessed during the
OGTT, and the rate of gastric emptying correlated to the GIP levels.
In summary, KBP-042 reduces plasma incretin levels during OGTT,
directly inhibits insulin and glucagon release from the islets of
Langerhans (17), and reduces gastric emptying. These effects can
also explain the reduced insulin levels in the OGTT, but not in the
IVGTT. The reduced gastric emptying can mediate a beneficial
effect on postprandial glucose levels, which along with fasting
plasma glucose levels are very important factors in the reduction of
risks related to hyperglycemia.
To formally assess the suggested increase in insulin action we per-
formed a hyperinsulinemic–euglycemic clamp study. The reduced
GIR seen in the HFD group compared with ND was expected since
obesity is negatively correlated to insulin sensitivity and GIR (2).
The large increase in GIR after treatment with KBP-042 illustrated
the increase in insulin sensitivity. The KBP-042-induced weight loss
could explain a large increase in GIR. However, here the rats treated
with KBP-042 had similar body weight to the ND, but with a signif-
icantly increased GIR. This could suggest that insulin sensitivity is
increased beyond what would be expected from weight loss,
although this has to be further tested in weight-matched animals
receiving the same diet.
In conclusion, KBP-042 induced a sustained weight loss over 8
weeks in obese prediabetic rats but not in pair-fed animals, leading
to reduction in adipose tissues, ectopic TAG deposition, improved
glucose tolerance, and improved insulin action. The combination of
a weight-reducing and insulin-sensitizing agent is to our knowledge
unique. KBP-042 thus shows great promise for the treatment of type
2 diabetes and obesity due to its multiple beneficial effects on sev-
eral aspects of the metabolic syndrome.O
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